ALLO - Allogene Therapeutics

-

$undefined

N/A

(N/A)

Allogene Therapeutics NASDAQ:ALLO Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of 'off-the-shelf' CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.

Location: | Website: www.allogene.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

241.4M

Cash

444.6M

Avg Qtr Burn

-57.18M

Short % of Float

25.79%

Insider Ownership

17.48%

Institutional Own.

80.72%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Cemacabtagene Ansegedleucel (cema-cel) Details
Cancer, Diffuse large B cell lymphoma

Phase 2

Data readout

ALLO-647 (Anti-CD52 mAb) Details
Cancer, Diffuse large B cell lymphoma

Phase 2

Update

Phase 1

Data readout

ALLO-316 (CD70) Details
Renal cell carcinoma, Cancer, Solid tumor/s

Phase 1

Data readout

ALLO-605 (BCMA) Details
Multiple myeloma, Cancer

Phase 1

Update

ALLO-715 (BCMA) Details
Cancer, Multiple myeloma

Phase 1

Update

IND

Submission